Krensavage Asset Management, LLC / ENTA
Krensavage Asset Management, LLC’s Enanta Pharmaceuticals Inc Position
Does Krensavage Asset Management, LLC own Enanta Pharmaceuticals Inc (ENTA)? Yes — 2.87M shares worth $36M (+14.16% of its 13F portfolio) as of Q1 2026, up from 2.77M shares the prior filed quarter.
Position Value
$36M
Q1 2026
Shares
2.87M
% of Portfolio
+14.16%
Quarters Held
29
currently held
Position History ENTA
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q1 2026 | 2.87M | $36M | +14.16% |
| Q4 2025 | 2.77M | $44M | +15.41% |
| Q3 2025 | 2.11M | $25M | +10.78% |
| Q2 2025 | 2.11M | $16M | +8.46% |
| Q1 2025 | 2.12M | $12M | +6.46% |
| Q4 2024 | 2.12M | $12M | +7.20% |
| Q3 2024 | 1.50M | $16M | +8.70% |
| Q2 2024 | 1.25M | $16M | +7.45% |
| Q1 2024 | 1.12M | $20M | +8.71% |
| Q4 2023 | 742.8K | $7M | +2.48% |
| Q3 2023 | 735.1K | $8M | +3.02% |
| Q2 2023 | 687.6K | $15M | +4.66% |
| Q1 2023 | 603.3K | $24M | +7.41% |
| Q4 2022 | 594.8K | $28M | +8.55% |
| Q3 2022 | 589.4K | $31M | +9.73% |
| Q2 2022 | 624.8K | $30M | +9.76% |
| Q1 2022 | 548.8K | $39M | +13.46% |
| Q4 2021 | 564.1K | $42M | +14.63% |
| Q3 2021 | 936.8K | $53M | +16.69% |
| Q2 2021 | 939.6K | $41M | +14.04% |
| Q1 2021 | 862.8K | $43M | +14.73% |
| Q4 2020 | 858.8K | $36M | +10.56% |
| Q3 2020 | 825.3K | $38M | +12.03% |
| Q2 2020 | 763.1K | $38M | +10.42% |
| Q1 2020 | 700.3K | $36M | +11.58% |
| Q4 2019 | 489.4K | $30M | +10.32% |
| Q3 2019 | 498.9K | $30M | +11.51% |
| Q2 2019 | 479.6K | $40M | +13.13% |
| Q1 2019 | 476.0K | $45M | +12.29% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Krensavage Asset Management, LLC’s full portfolio or all institutional holders of ENTA.